The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

The FDA has approved popular antiobesity drug Ozempic to help protect patients with type 2 diabetes from kidney disease.

The approval is based on results from the Phase III FLOW trial demonstrating Ozempic reduced the risk of severe kidney outcomes by 24% compared to placebo, including kidney failure, reduction in ...

The US Food and Drug Administration on Tuesday approved Ozempic for adults with type 2 diabetes and chronic kidney disease (CKD). The drug is now indicated specifically to treat kidney failure, ...

Lægemiddelstyrelsen i USA, FDA, har tirsdag godkendt Novo Nordisks diabetesmiddel Ozempic til behandling af kronisk ...

Det er USA's føderale fødevare- og lægemiddelmyndighed (FDA), der har godkendt medicinen, som er blevet udviklet og bliver solgt af Novo Nordisk. Dermed kan lægemidlet bruges til at behandle endnu ...

Flere patienter i USA kan nu bruge det danske lægemiddel Ozempic, der er godkendt til brug ved nyresygdom. Ozempic er tirsdag ...

This story incorporates reporting fromdevdiscourse, WJON and KIMT.Novo Nordisk has settled a lawsuit with Minnesota, agreeing ...

Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much ...

Novomidlet amycretin i sprøjteform giver i nyt studie et vægttab på 22 procent efter 36 uger. Aktien stiger. Novo Nordisk har fredag offentliggjort data fra et studie med vægttabsmidlet amycretin i ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.

Wegovy og Ozempic er udvalgt til prisforhandlinger i USA. Novo har seks uger til at vælge, om man vil deltage Omkring 2,3 ...